mesothelioma treatments

  • | |

    New Mesothelioma Drug Kills Cancer Stem Cells

    Citing “significant enthusiasm within the mesothelioma community”, the manufacturers of a promising new mesothelioma drug say they have begun a major test of the drug in patients. Massachusetts-based Verastem, Inc. focuses on drugs that fight cancer by attacking the stem cells that give rise to them. Earlier this summer, the FDA granted orphan drug status to their stem cell inhibitor, defactinib, for the treatment of mesothelioma. The designation, which is reserved for drugs that fight the rarest of diseases, helps pave the way for testing and faster approval, depending on the results of clinical trials. “Development of a drug that preferentially kills cancer stem cells is a promising approach, as many standard-of-care treatments have been shown to either have no…

  • | |

    Inflammation Both “Friend and Foe” in Mesothelioma

    An immune system response that causes mesothelioma symptoms such as fever, fatigue, and weight loss may also be helpful to clinicians as a way to find and treat the disease. Scientists with The Asbestos Diseases Research Institute in Sydney, Australia make that case that both systemic inflammation (throughout the body) and at the site of a tumor – has long been associated with mesothelioma and other cancers. Inflammation results when the body attempts to address the imbalances of cancer by producing more of certain immune system cells. Some inflammatory markers, such as CD+8 T-cells and C-reactive protein, have been linked to better prognosis in mesothelioma. Other inflammatory markers, such as certain macrophages and a high neutrophil-to-lymphocyte ratio, can signal the…

  • | |

    Mesothelioma Study Finds New Treatment Target

    Immunotherapy, which involves reprogramming T-cells to find and attack cancer cells, is one of the fastest-growing areas of cancer research. One of the biggest challenges of immunotherapy is how to harness the power of T-cells against cancer without also turning them against healthy cells. A new study conducted in Switzerland and published in the Journal of Translational Medicine addressed the problem by reprogramming T-cells to recognize and attack mesothelioma cells that express a specific protein. Fibroblast Activation Protein (FAP) is expressed on the surface of tumor-associated fibroblast cells which are found in the connective tissue of mesothelioma tumors. FAP is also found in mesothelioma cells and may play a role in the start of cancer, as well as the growth…

  • | |

    Could Statin Drugs Help Fight Mesothelioma?

    A new study suggests that some of the most popular drugs used to treat high cholesterol may also help combat deadly malignant mesothelioma. That finding comes from Japanese research, published recently in the medical journal, Cancer Letters. The study found a “synergistic effect” in mesothelioma cells between two statin drugs, atorvastatin (Lipitor) and simvastatin (Zocor) and gamma tocotrienol (y-T3), a form of Vitamin E. “Statin+y-T3 combinations induced greater cell growth inhibition more than each single treatment,” write the authors in the summary of their findings. The combination of statin drugs and gamma-tocotrienol appears to work by inhibiting an important metabolic pathway inside the mesothelioma cells, making it impossible for them to synthesize or utilize certain critical molecules. When the researchers…

  • | |

    Scientists Test New Skin Delivery for Mesothelioma Drug

    Researchers at Griffith University are working on a new kind of mesothelioma treatment – one that could be delivered through the skin. The report in the Courier Mail makes reference to animal research on “certain small molecules” that reportedly have the potential to penetrate the skin and target the mitochondria of mesothelioma cells. Mitochondria are one of the most important power sources for cells, producing adenosine triphosphate, a source of chemical energy. The Griffith University project, under the leadership of Medical Professor Jiri Neuzil, is focusing on a drug that would be applied to the skin as a patch or cream. The drug would enter the blood stream through the skin and would target only mesothelioma cells. Studies of the…

  • |

    New Approach to Decrease Mesothelioma Symptom

    Draining off excess lung fluid with an indwelling catheter may be a better way to deal with this mesothelioma symptom than surgery, according to a new study. Pleural effusion, a build-up of fluid between the two layers of the lining around the lungs, is a common side effect of several cancers, including malignant pleural mesothelioma. Approximately half of all patients with metastatic cancer develop pleural effusion, which can have a dramatic impact on quality of life by inhibiting a person’s ability to breathe freely. Many mesothelioma patients also experience chest pain and fatigue as a result of pleural effusion. If untreated, pleural effusion can lead to pneumonia or lung collapse. Some mesothelioma patients with pleural effusion are treated with pleurodesis,…

  • | |

    FDA Approval Could Mean New Choice for Mesothelioma Patients

    A newly-approved drug for late-stage lung cancer may have implications for people with malignant mesothelioma, as well. The FDA recently announced its approval of afatinib, a drug which blocks epidermal growth factor receptor (EGFR) expression in cancer cells. Many types of cancer, including about half mesothelioma cases, express a specific type of mutation on the EGFR gene that causes tumors to grow even faster. Because of this, EGFR has been a focus for biomarker research in mesothelioma, as well as in a number of other cancers. In clinical trials, afatinib (brand name Gilotrif), significantly extended progression-free survival in non-small cell lung cancer patients versus the more common pemetrexed/cisplatin chemotherapy combination. Over a 12-month period, the progression-free survival of lung cancer…

  • | | |

    New Mesothelioma Treatment Targets Growth Factors

    On the brink of a predicted “third wave” of mesothelioma cases in Australia, Australian scientists are testing a new kind of treatment that combines drugs and gene therapy. Australia has long had one of the highest per capita rates of mesothelioma, the most deadly of asbestos-linked diseases. Historically, mesothelioma cases occurred first among people who worked with asbestos in Australia’s mines. Later, new cases developed among people in industrial jobs like construction or shipbuilding. But, in recent years, there is growing concern about a third wave of mesothelioma cases among renovators, do-it-yourself homeowners and others with relatively low levels of exposure. In anticipation of this problem, scientists at Flinders University are working on a mesothelioma treatment that targets “key growth factors…

  • | |

    Mesothelioma Report Suggests Clinical Trials Better Than Surgery

    Doctors in the Department of Respiratory medicine at York Teaching Hospital in the UK are taking a hard stance against the surgical treatment of malignant pleural mesothelioma. In a recent article in the journal Thorax, the group contends that the research surrounding mesothelioma surgery is largely flawed and that the majority of mesothelioma patients would be better served if their doctors suggested alternatives. “Belief that the modest survival times reported after radical surgery, whether alone or as part of multimodal therapy, are longer than they would have been without surgery relies on data from highly selected, uncontrolled, retrospectively analyzed case series,” they write. They point out that the only randomized study, the Mesothelioma and Radical Surgery (MARS) trial showed no measurable…

  • | |

    FDG PET-CT Results Could Lead to Improved Mesothelioma Treatment

    In a recent study, researchers say a better understanding of certain diagnostic criteria could result in more targeted treatments for malignant mesothelioma. In a recent published report, doctors from the medical school at Dicle University in Diyarbakir, Turkey measured the relationship between PET-CT scan results and survival in 177 patients with malignant pleural mesothelioma. The patients were diagnosed between April 2007 and April 2011. They had a mean age of 55.4 and most (56%) were male. Patients in the study all had FDG PET-CT scans before beginning their mesothelioma treatment. FDG PET-CT scanning is a powerful imaging tool for mesothelioma and other cancers that combines a radioactive tracer with a combination of positron emission tomography and computed tomography scanning.  Because…